Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beclometasone/formoterol - Chiesi Farmaceutici

Next Previous
X
Search
Drug Profile

Beclometasone/formoterol - Chiesi Farmaceutici

Alternative Names: Beclometasone dipropionate/formoterol fumarate dihydrate; Beclomethasone/formoterol; CHF 1535 35/4 NEXTHALER®; CHF-1535; Combair; Formodual; Formoterol/beclometasone; Fostair; Fostair NEXThaler; Foster; Foster Nexthaler; Foster Spray; Fostex; Fostex NEXThaler; Innovair; Innovair NEXThaler; Inuvair; Inuver; Inuxair; Kantos; Kantos Master; Kantos NEXThaler

Latest Information Update: 13 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chiesi Farmaceutici
  • Developer Chiesi Farmaceutici; Chiesi USA
  • Class Antiasthmatics; Corticosteroids; Ethanolamines; Pregnadienetriols; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 19 May 2023 Efficacy and adverse event data from the phase III FORTUNE trial for Asthma presented at the 119th International Conference of the American Thoracic Society (ATS-2023)
  • 01 Feb 2023 Chiesi Farmaceutici completes the phase III FEEL trial for Asthma (In adults, In the elderly) in Italy (Inhalation, Solution) (NCT04886999) (EudraCT2021-001449-11)
  • 05 Oct 2022 Chiesi Farmaceutici initiates a phase III FORCE2 trial in Asthma (Inhalation) in USA (NCT05292586)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top